about
Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature.The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy."One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.Clinical value of O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma.PET Imaging in Patients with Meningioma - Report of the RANO/PET Group.From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.Advances in neuro-oncology imaging.Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET).Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomasDetection of remote neuronal reactions in the Thalamus and Hippocampus induced by rat glioma using the PET tracer cis-4-[¹⁸F]fluoro-D-proline.Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.Clinical value of 2-deoxy-[18F]fluoro-D-glucose positron emission tomography in patients with cervical spondylotic myelopathy.Amino acid PET and MR perfusion imaging in brain tumours.Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas.18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis.Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.Coma and cerebral imagingVolumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI.Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans.Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions.Reproducibility of O-(2-(18)F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas.O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis.Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.5-Aminolevulinic Acid and (18)F-FET-PET as Metabolic Imaging Tools for Surgery of a Recurrent Skull Base Meningioma.Adapting MR-BrainPET scans for comparison with conventional PET: experiences with dynamic FET-PET in brain tumours.Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions.Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation.Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging.Hypermetabolism in 18F-FDG PET predicts favorable outcome following decompressive surgery in patients with degenerative cervical myelopathy.Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
P50
Q30599841-522D8FDA-9E8F-4F6B-A262-640A8F0673C4Q31156299-0C7AFE50-5ECC-497C-BB84-1AA388EF10C3Q33405170-BF498A2C-2ED3-405B-B547-5DD27013DB28Q34571816-6B79CD64-DB64-4650-A87D-FB37D07B4E05Q34682187-A4F05808-E975-4E70-B784-F8F9C7E25FB3Q35679377-2D9E4BF1-0A91-45E4-827A-C81E4C26FC71Q36107374-49BC7123-99BA-4CCD-9353-F44FCECCC506Q36339461-4A75CA2A-73C4-4EA5-A179-EAC74B5F3704Q36383638-8BF7AC1C-A4F6-44BD-8A4E-19B7826B7455Q36785136-07C2EDA8-5F7A-4128-9735-92E4B0452127Q36839936-E7464AA3-7BAA-401D-B7ED-2398FD19F7CFQ37037922-FC3B487B-4DBF-484B-A345-E3FD6D186891Q37312721-DC007D72-1A66-46B0-8949-C92BC66B1E94Q38118352-233CF46F-A4FE-453E-9CE9-557032A35704Q38691946-12A008CC-AACF-4D5E-9C70-9711AADB539FQ38747089-7C609628-0A71-48C4-920A-B5ABD782EB96Q38809950-F66D961E-A8F5-48C0-AF06-FBC0AE6A108FQ38815396-5C49F5B8-0BB6-4086-99FA-B7CDEAA8291DQ39005573-8BA0CFE7-35A2-4F45-9A03-C2A67AF16CCEQ39031636-307AA09E-5EEF-4C4C-8F45-43A7ED37C790Q39181712-412CEB5D-2F86-4B15-83D3-8F802E466B49Q39340154-0EEACD71-DFB8-4F50-9B93-08AF8607418AQ40232491-F2C614E8-FA83-4684-8D5A-6C5AE0BACBE7Q40333907-6DE554FD-4337-4557-A824-3A89E97DEE7CQ41045513-E55A2561-1DD2-418E-8829-6A2B75D9C8C7Q41154181-C0805289-9BEB-49FB-8B6A-25172592878AQ41827530-2C2AD50F-C96B-4477-9FBE-67A08CF7DFE4Q42137779-ABBEE096-F690-4F68-B48E-5968192771FFQ42234940-62D3477D-6419-4155-842F-3EB8C3169927Q42391408-A47E31E3-23BF-4092-9A7E-21F04ACA949BQ43120590-184FDE3E-4E0F-4D53-BC2D-3CDD505C1F83Q43699515-37964191-17F1-4201-9519-86ABF79C40BBQ43959280-3D794784-21A5-40E6-B1C2-6EF8791BC129Q44314553-CA18396A-D0E0-4759-BA36-D37BE6041B55Q44461998-43F3985C-816E-4013-9BAF-E3D3859ADA9FQ45362937-E9DFB2B6-005C-4A49-9B2E-ED525AFC0F35Q46097591-2587A4E8-6395-49F3-98F3-1BBC7B87E23AQ46722538-97A69877-176B-49A6-9FA0-63C0AC3F67DDQ46830923-25F3B56B-C65C-4F37-8013-096F32263D0EQ46922149-B91900F5-3B1C-48B5-B2AD-FB563546A489
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Norbert Galldiks
@ast
Norbert Galldiks
@en
Norbert Galldiks
@es
Norbert Galldiks
@nl
Norbert Galldiks
@sl
type
label
Norbert Galldiks
@ast
Norbert Galldiks
@en
Norbert Galldiks
@es
Norbert Galldiks
@nl
Norbert Galldiks
@sl
prefLabel
Norbert Galldiks
@ast
Norbert Galldiks
@en
Norbert Galldiks
@es
Norbert Galldiks
@nl
Norbert Galldiks
@sl
P214
P106
P21
P214
P31
P496
0000-0002-2485-1796
P735
P7859
viaf-210406972